Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Anchiano Therapeutics Ltd ADR (ANCN)

Anchiano Therapeutics Ltd ADR (ANCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,948
  • Shares Outstanding, K 7,420
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,610 K
  • 60-Month Beta 0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.77
Trade ANCN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.46
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/06/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +243,758.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.60 +81.15%
on 03/04/21
8.20 -42.56%
on 03/16/21
-0.18 (-3.68%)
since 02/16/21
3-Month
1.65 +185.45%
on 01/04/21
10.55 -55.36%
on 02/10/21
+2.09 (+79.77%)
since 12/16/20
52-Week
0.51 +817.06%
on 03/20/20
10.55 -55.36%
on 02/10/21
+4.06 (+622.84%)
since 03/16/20

Most Recent Stories

More News
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing

Anchiano s hareholders approve all resolutions at shareholder meeting

ANCN : 75.36 (+5.37%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of ANCN, JWS, GXGX, and ALSK Mergers

WILMINGTON, Del., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

JWS : 14.75 (-0.74%)
GXGX : 10.20 (+27.18%)
ALSK : 3.40 (+0.29%)
ANCN : 75.36 (+5.37%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of INFO, PS, CATM, and ANCN Mergers

WILMINGTON, Del., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

ANCN : 75.36 (+5.37%)
CATM : 39.01 (+0.08%)
PS : 22.45 (+0.13%)
INFO : 20.42 (+0.86%)
ANCHIANO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Anchiano Therapeutics Ltd. - ANCN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Anchiano Therapeutics Ltd. (NasdaqGS: ANCN)...

ANCN : 75.36 (+5.37%)
Moore Kuehn Encourages BEAT, AJRD, ANCN, and RNET Investors to Contact Law Firm

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning...

BEAT : 2.26 (+4.63%)
AJRD : 57.99 (+1.42%)
ANCN : 75.36 (+5.37%)
RNET : 9.60 (-2.24%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Anchiano Therapeutics Ltd. Merger

WILMINGTON, Del., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Anchiano Therapeutics Ltd. (“Anchiano”) (NASDAQ CM: ANCN ) regarding possible breaches...

ANCN : 75.36 (+5.37%)
Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement

Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need

ANCN : 75.36 (+5.37%)

Business Summary

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapies to treat cancer. The company's product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. It operates primarily...

See More

Key Turning Points

3rd Resistance Point 10.67
2nd Resistance Point 9.44
1st Resistance Point 7.07
Last Price 75.36
1st Support Level 3.47
2nd Support Level 2.24
3rd Support Level N/A

See More

Last Price 75.36
52-Week High 10.55
Fibonacci 61.8% 6.72
Fibonacci 50% 5.53
Fibonacci 38.2% 4.35
52-Week Low 0.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar